[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:digestive-system-neuroendocrine-tumor:mki67-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Digestive System Neuroendocrine Tumor","MKI67 Gene",4,[8,16,23,30],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06395402","177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry",[12],"Phase 2","RECRUITING","2026-08-26T02:15:45.413021Z","2026-05-05T02:43:29.074931Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04609592","Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery",[20],"Phase 1","2026-08-03T01:59:18.089574Z","2026-05-05T02:43:28.703397Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06016855","Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors",[27],"Phase 4","2026-08-26T02:16:42.787115Z","2026-05-05T02:43:27.860078Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT04090034","Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors",[],"2026-08-26T02:17:30.961790Z","2026-05-13T02:55:06.233960Z"]